The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Human Recombinant DNA–Derived Antihemophilic Factor (Factor VIII) in the Treatment of Hemophilia A
Abstract
BACKGROUND: Current treatment of hemophilia A, a hereditary disorder affecting approximately 1 in 10,000 males, relies on plasma-derived factor VIII concentrates. We tested the safety and efficacy of a recombinant factor VIII preparation for the treatment of this disorder. METHODS: We conducted the investigation in three stages: comparing the pharmacokinetics of plasma-derived and recombinant factor VIII, assessing the efficacy of recombinant factor VIII for home therapy, and assessing its efficacy for major surgical procedures and hemorrhage. A total of 107 subjects with hemophilia, 20 of whom had not been treated previously, enrolled in the investigation. RESULTS: The in vivo recovery and elimination half-lives of recombinant factor VIII equaled or exceeded those of plasma-derived factor VIII. Seventy-six subjects participated in a home-treatment program, using recombinant factor VIII for 69 to 807 days (median, 618); home diaries of 56 subjects treated for 5 months were analyzed. Of 540 bleeding episodes, 399 (73.9 percent) required only one treatment with recombinant factor VIII. The projected annual consumption of recombinant factor VIII was similar to that of plasma-derived factor VIII concentrate. Twenty-six subjects received recombinant factor VIII for 22 surgical procedures and 10 serious hemorrhages; hemostasis was excellent in all cases. De novo formation of inhibitors occurred in only 1 of 85 previously treated subjects. Inhibitor antibodies also developed in 6 of 21 children, 20 of whom had not previously been treated; 5 had low levels (less than or equal to 7.5 Bethesda units) despite continued treatment with recombinant factor VIII. There was no evidence of new formation of antibody to foreign proteins, and recombinant factor VIII was well tolerated. CONCLUSIONS: Recombinant factor VIII has biologic activity comparable to that of plasma factor VIII and is safe and efficacious for the treatment of hemophilia A.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular cloning of a cDNA encoding human antihaemophilic factor
Toole, J. J., Knopf, J. L., Wozney, J. M., Sultzman, L. A., Buecker, J. L., Pittman, D. D., Kaufman, R. J., Brown, E., Shoemaker, C., Orr, E. C., et al. (1984) · Nature · doi:10.1038/312342a0 · Cited by 925
Langdell, R. D., Wagner, R. H., & Brinkhous, K. M. (1953) · PubMed · Cited by 736
Expression of active human factor VIII from recombinant DNA clones
Wood, W. I., Capon, D. J., Simonsen, C. C., Eaton, D. L., Gitschier, J., Keyt, B., Seeburg, P. H., Smith, D. H., Hollingshead, P., Wion, K. L., et al. (1984) · Nature · doi:10.1038/312330a0 · Cited by 694
McMillan, C., Shapiro, S., Whitehurst, D., Hoyer, L., Rao, A., & Lazerson, J. (1988) · Blood · doi:10.1182/blood.v71.2.344.344 · Cited by 169
Use of Recombinant Antihemophilic Factor in the Treatment of Two Patients with Classic Hemophilia
White, G. C., McMillan, C. W., Kingdon, H. S., & Shoemaker, C. B. (1989) · New England Journal of Medicine · doi:10.1056/nejm198901193200307 · Cited by 164
The natural history of factor VIII inhibitors in patients with hemophilia A.
Gill, F. (1984) · PubMed · Cited by 85
Efficacy of Self-Therapy in Hemophilia
Levine, P. H. (1974) · New England Journal of Medicine · doi:10.1056/nejm197412262912604 · Cited by 79
Self-citationSchwarzinger, I., Pabinger, I., Korninger, C., Haschke, F., Kundi, M., Niessner, H., & Lechner, K. (1987) · American Journal of Hematology · doi:10.1002/ajh.2830240303 · Cited by 74
Giles, A. R., Tinlin, S., Hoogendoorn, H., Fournel, M., Ng, P., & Pancham, N. (1988) · Blood · doi:10.1182/blood.v72.1.335.bloodjournal721335 · Cited by 45
Self-citation
Cited by
The hemophilias--from royal genes to gene therapy
Mannucci, P. M., & Tuddenham, E. G. D. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106073442307 · Cited by 1,110
Self-citationIncidence of development of factor VIII and factor IX inhibitors in haemophiliacs
Ehrenforth, S., Kreuz, W., Linde, R., Funk, M., Güngor, T., Krackhardt, B., Kornhuber, B., & Scharrer, I. (1992) · The Lancet · doi:10.1016/0140-6736(92)90874-3 · Cited by 605
Self-citationMolecular and Cellular Biology of Blood Coagulation
Flier, J. S., Underhill, L. H., Furie, B., & Furie, B. C. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203193261205 · Cited by 530
Lusher, J. M., Arkin, S., Abildgaard, C. F., & Schwartz, R. S. (1993) · New England Journal of Medicine · doi:10.1056/nejm199302183280701 · Cited by 476
Self-citationBiochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII
Pittman, D., Alderman, E., Tomkinson, K., Wang, J., Giles, A., & Kaufman, R. (1993) · Blood · doi:10.1182/blood.v81.11.2925.2925 · Cited by 268
Metadata
- Authors
- Schwartz, R. S., Abildgaard, C. F., Aledort, L. M., Arkin, S., Bloom, A. L., Brackmann, H. H., Brettler, D. B., Fukui, H., Hilgartner, M. W., Inwood, M. J., Kasper, C. K., Kernoff, P. B. A., Levine, P. H., Lusher, J. M., Mannucci, P. M., Scharrer, I., MacKenzie, M. A., Pancham, N., Kuo, H. S., & Allred, R. U.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1990-12-27
- Volume
- 323
- Issue
- 26
- Pages
- 1800-1805
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2324395680
- Cited by
- 267
- References
- 11
- FWCI
- 11.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Human Recombinant DNA–Derived Antihemophilic Factor (Factor VIII) in the Treatment of Hemophilia A. https://app.cochat.ai/papers/10.1056/nejm199012273232604
- The paper
- Schwartz, R. S., Abildgaard, C. F., Aledort, L. M., Arkin, S., Bloom, A. L., Brackmann, H. H., Brettler, D. B., Fukui, H., Hilgartner, M. W., Inwood, M. J., Kasper, C. K., Kernoff, P. B. A., Levine, P. H., Lusher, J. M., Mannucci, P. M., Scharrer, I., MacKenzie, M. A., Pancham, N., Kuo, H. S., & Allred, R. U. (1990). Human Recombinant DNA–Derived Antihemophilic Factor (Factor VIII) in the Treatment of Hemophilia A. New England Journal of Medicine. https://doi.org/10.1056/nejm199012273232604
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.